Pregnenolone

Generic Name: Pregnenolone

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₃₂O_₂

CAS Number: 145-13-1

Unique Ingredient Identifier: 73R90F7MQ8

Background: A 21-carbon steroid, derived from cholesterol and found in steroid hormone-producing tissues. Pregnenolone is the precursor to gonadal steroid hormones and the adrenal corticosteroids.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A New Intervention to Improve Function in Veterans With Anxiety and Depression

Phase 2

Not yet recruiting

Conditions: Anxiety and Depression

Interventions: Drug: Pregnenolone
Drug: Placebo

First Posted Date: 2024-01-03

Last Posted Date: 2024-10-22

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 84

Registration Number: NCT06188923

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial

Phase 2

Not yet recruiting

Conditions: Chronic Low Back Pain

Interventions: Drug: DHEA
Drug: Placebo
Drug: Pregnenolone

First Posted Date: 2023-07-07

Last Posted Date: 2024-04-05

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 108

Registration Number: NCT05935761

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

Pregnenolone for the Treatment of Alcohol Use Disorder

Phase 2

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Placebo
Drug: Pregnenolone

First Posted Date: 2023-03-23

Last Posted Date: 2024-06-11

Lead Sponsor: Yale University

Target Recruit Count: 150

Registration Number: NCT05781009

Locations: 🇺🇸
The Yale Stress Center: Yale University, New Haven, Connecticut, United States

Novel Intervention for Chronic Complex TBI in OEF/OIF/OND Veterans

Phase 2

Not yet recruiting

Conditions: Traumatic Brain Injury
TBI

Interventions: Drug: Pregnenolone
Drug: Placebo

First Posted Date: 2023-01-05

Last Posted Date: 2024-07-15

Lead Sponsor: Christine Marx, MD

Target Recruit Count: 108

Registration Number: NCT05671692

Locations: 🇺🇸
Duke University School of Medicine, Durham, North Carolina, United States
🇺🇸
Durham VA Health Care System, Durham, North Carolina, United States

Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

Phase 2

Recruiting

Conditions: Anxiety Depression
HIV
Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Pregnenolone

First Posted Date: 2022-10-07

Last Posted Date: 2024-06-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 120

Registration Number: NCT05570812

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Neurosteroids for PTSD in Veterans

Phase 2

Recruiting

Conditions: Posttraumatic Stress Disorder

Interventions: Drug: Placebo
Drug: Pregnenolone

First Posted Date: 2019-01-10

Last Posted Date: 2024-10-10

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 90

Registration Number: NCT03799562

Locations: 🇺🇸
Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States

A Neurosteroid Intervention for Menopausal and Perimenopausal Depression

Phase 1

Active, not recruiting

Conditions: Major Depressive Disorder
Menopause
Perimenopause

Interventions: Drug: Pregnenolone
Drug: Placebo

First Posted Date: 2018-04-23

Last Posted Date: 2024-12-19

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 123

Registration Number: NCT03505905

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

Pilot Trial of Pregnenolone in Autism

Phase 2

Recruiting

Conditions: Autism Spectrum Disorder
Autism

Interventions: Drug: Placebo
Drug: Pregnenolone

First Posted Date: 2015-12-11

Last Posted Date: 2024-06-20

Lead Sponsor: Stanford University

Target Recruit Count: 40

Registration Number: NCT02627508

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders

Phase 4

Completed

Conditions: Alcohol Use Disorder
Bipolar Disorder
Schizoaffective Disorder Bipolar Type

Interventions: Drug: Placebo
Dietary Supplement: Citicoline
Drug: Pregnenolone

First Posted Date: 2015-10-21

Last Posted Date: 2024-10-09

Lead Sponsor: Sherwood Brown, MD, PhD

Target Recruit Count: 96

Registration Number: NCT02582905

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
The University of Texas Rio Grande Valley, Edinburg, Texas, United States

Pregnenolone and Marijuana Dependence

Phase 2

Completed

Conditions: Marijuana Dependence

Interventions: Drug: Pregnenolone
Other: Placebo

First Posted Date: 2015-05-12

Last Posted Date: 2018-06-18

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 21

Registration Number: NCT02439814

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy